Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 20/20 | 0.98 |
| ▸ | FAP | Q12884 | 9/20 | 0.80 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.77 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.67 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL295498 | 1.00 | DPP4 (0.98) | DPP4FAPDPP7DPP8DPP9 | |
| SCHEMBL3165078 | 0.99 | DPP4 (1.00) | DPP4FAPDPP7DPP8DPP9 | |
| SCHEMBL6832198 | 0.99 | DPP4 (1.00) | DPP4FAPDPP7DPP8DPP9 | |
| SCHEMBL6860819 | 0.99 | DPP4 (1.00) | DPP4FAPDPP7DPP8DPP9 | |
| SCHEMBL5987446 | 0.99 | DPP4 (1.00) | DPP4FAPDPP7DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL3259953 | 0.90 | DPP4 (0.98) | DPP4FAPDPP7DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL3151403 | 0.90 | DPP4 (0.98) | DPP4FAPDPP7DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL3151253 | 0.90 | DPP4 (0.98) | DPP4FAPDPP7 | |
| SCHEMBL3160316 | 0.89 | DPP4 (1.00) | DPP4FAPDPP7DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL5549130 | 0.89 | DPP4 (0.98) | DPP4FAPDPP7DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1862457-B1 | Fluoropyrrolidines as dipeptidyl peptidase inhibitors | SMITHKLINE BEECHAM CORP (US) | 2010-01-20 | — | — | EP | claimed |
| EP-1862457-A2 | Fluoropyrrolidines as dipeptidyl peptidase inhibitors | SmithKline Beecham Corporation (US) | 2007-12-05 | — | — | EP | claimed |
| US-20040171848-A1 | Fluoropyrrolidines as dipeptidyl peptidase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-09-02 | — | — | US | claimed |
| EP-3023095-B2 | DIRECT COMPRESSION FORMULATION AND PROCESS | NOVARTIS AG (CH) | 2023-11-08 | — | — | EP | disclosed |
| EP-3738585-A1 | DIRECT COMPRESSION FORMULATION AND PROCESS | NOVARTIS AG (CH) | 2020-11-18 | — | — | EP | disclosed |
| EP-2839832-A2 | Use of dipeptidyl peptidase IV inhibitors | Novartis AG (CH) | 2015-02-25 | — | — | EP | disclosed |
| US-20140287040-A1 | Formulation | NOVARTIS AG (CH) | 2014-09-25 | — | — | US | disclosed |
| US-20140205663-A1 | Direct Compression Formulation and Process | NOVARTIS AG (CH) | 2014-07-24 | — | — | US | disclosed |
| US-20130052239-A1 | Formulation | JOSHI YATINDRA (US) | 2013-02-28 | — | — | US | disclosed |
| US-20120294939-A1 | DIRECT COMPRESSION FORMULATION AND PROCESS | KOWALSKI JAMES (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120149639-A1 | USE OF A DPP-IV INHIBITOR TO REDUCE HYPOGLYCEMIC EVENTS | BALKAN BOERK (US) | 2012-06-14 | — | — | US | disclosed |
| US-20080038341-A1 | Free-flowing, cohesive tableting powder for direct compressed tablet; DPP-IV inhibitor and glitazone, in unit dosage form; acceptable dissolution profile; acceptable degrees of hardness, resistance to chipping, short disintegration time | KOWALSKI JAMES | 2008-02-14 | — | — | US | disclosed |
| EP-1862457-A2 | Fluoropyrrolidines as dipeptidyl peptidase inhibitors | SmithKline Beecham Corporation (US) | 2007-12-05 | — | — | EP | disclosed |
| US-20070254944-A1 | Use of Organic Compounds | NOVARTIS AG (CH) | 2007-11-01 | — | — | US | disclosed |
| EP-1406873-B1 | FLUOROPYRROLIDINES AS DIPEPTIDYL PEPTIDASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070149451-A1 | Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent | HOLMES DAVID G | 2007-06-28 | — | — | US | disclosed |
| US-20070066677-A1 | (2S,4s)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-I-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt and anhydrous crystalline forms thereof | SMITHKLINE BEECHAM CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-7132443-B2 | Fluoropyrrolidines as dipeptidyl peptidase inhibitors | SMITHKLINEBEECHAM CORPORATION (US) | 2006-11-07 | — | — | US | disclosed |
| US-20060210627-A1 | Direct compression formulation and process | PFEFFER SABINE | 2006-09-21 | — | — | US | disclosed |
| US-20040171848-A1 | Fluoropyrrolidines as dipeptidyl peptidase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149451-A1 | Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent | GIPR, DPP4, MC4R | DPP4 2/4885FAP 725/4885DPP7 9/4885 |
| US-20080038341-A1 | Free-flowing, cohesive tableting powder for direct compressed tablet; DPP-IV inhibitor and glitazone, in unit dosage form; acceptable dissolution profile; acceptable degrees of hardness, resistance to chipping, short disintegration time | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 207/4885DPP7 3/4885 |
| US-20040171848-A1 | Fluoropyrrolidines as dipeptidyl peptidase inhibitors | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 13/4885DPP7 3/4885 |
| US-20070066677-A1 | (2S,4s)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-I-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt and anhydrous crystalline forms thereof | PFAS, TTR, PNN | DPP4 283/4885FAP 28/4885DPP7 943/4885 |
| US-20140205663-A1 | Direct Compression Formulation and Process | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 97/4885DPP7 3/4885 |
| US-20070254944-A1 | Use of Organic Compounds | DPP4, DPP8, DPP3 | DPP4 1/4885FAP 97/4885DPP7 4/4885 |
| US-20140287040-A1 | Formulation | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 22/4885DPP7 3/4885 |
| US-20130052239-A1 | Formulation | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 22/4885DPP7 3/4885 |
| US-20120294939-A1 | DIRECT COMPRESSION FORMULATION AND PROCESS | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 97/4885DPP7 3/4885 |
| US-20120149639-A1 | USE OF A DPP-IV INHIBITOR TO REDUCE HYPOGLYCEMIC EVENTS | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 135/4885DPP7 3/4885 |
| US-20060210627-A1 | Direct compression formulation and process | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 131/4885DPP7 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.